Ixazomib-Based Triplet Therapy for Newly Diagnosed Multiple Myeloma
The efficacy of triplet therapy with ixazomib plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma was the focus of a phase I/II clinical trial presented at the 2017 European Hematology Association (EHA) Annual Congress (Abstract S780). Paul Richardson, MD, of the Dana-Farber Cancer Institute, and colleagues demonstrated that patients who did not undergo stem cell transplantation exhibited durable responses to this all-oral approach to induction/remission therapy.
In total, 64 patients were enrolled, and 40 patients remained on study treatment without early withdrawal for stem cell transplantation. Median progression-free survival was 24.9 months. The 2-year Kaplan-Meier estimate for overall survival was 92%. Overall, 78% of patients experienced grade 3 or higher adverse events, most commonly rash, hyperglycemia, and neutropenia.
After induction therapy, 18 patients followed with maintenance therapy with single-agent ixazomib; they exhibited an overall response rate of 94%. The rate of complete response plus very good partial response was 89%. Most adverse events began during induction therapy but were infrequent during maintenance therapy.
In an interview with The ASCO Post, Dr. Richardson stated: “Ixazomib plus lenalidomide and dexamethasone resulted not only in high quality of responses using a twice-a-week schedule, but also in an encouraging deepening of responses over time in patients who did not receive a stem cell transplant.”